AIM To evaluate the changes and significances of von Willebrand Factor(vWF) and alpha-Granule Membrance Protein-140(GMP-140)in unstable angina pectoris patients after percutaneous coronary intervention(PCI).
Blood samples were obtained at baseline and after 4 weeks of Fluvastatin or placebo therapy, patients TXB2 was detected by Immune Antigen-antibody complex test,GMP-140 was detected by immunoadsorption test.
To evaluate the optimeal target anticoagulation intensity and reduce the risk of thromboemboli and bleeding during perioperation after mechanical heart valve rephacement, hematologic assays including prothrombin time (PT), activity of factor X, antithrombin Ⅲ, D dimer, fibrinogen (Fg), platelet alpha granular membrane protein (GMP 140) were performed before operation, during cardiopulmonary bypass, and at the postoperative day 1,3,7 and 14 in 40 patients receiving warfarin treatment.
为探讨人工机械瓣膜围术期合理抗凝治疗, 减少血栓栓塞与抗凝出血并发症, 对40 例患者术前、术中及术后第1、3、7、15 d 凝血酶原时间(PT)、血浆凝血因子X活性、抗凝血酶Ⅲ(AT Ⅲ)、D-二聚(D-dim er)、纤维蛋白原含量(Fg) 及血浆血小板α颗粒蛋白(GMP-140) 改变进行了动态监测。
Methods With high-resolution ultrasound flow mediated dilation of the brachial artery(FMD)was measured in transient ischemic attacks(n=20)and 20 health person of control group. All of the yon wille- brand factor(vWF),6-K-PGF1a and plateletα-granular membrane protein-140(GMP-140)were assayed at the same time.